An EUA for Casirivimab and Imdevimab for COVID-19

Date: December 28, 2020 Issue #:  1614Summary:  The FDA has issued an Emergency Use Authorization (EUA) for Regeneron ' s investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) to be administered together by IV infusion for treatment of mild to moderate COVID-19 in adults and pediatric patients ( ≥12 years old and weigh ≥40 kg) who are at high risk of progressing to severe COVID-19 and/or hospitalization (see Table 1). Bamlanivimab (LY-CoV555; Lilly), another monoclonal antibody, received an EUA for the same indication on November 9, 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: casirivimab COVID-19 imdevimab Source Type: research